Research Research groups Clinical pharmacology - special populations

About this research group

This research group uses innovative methods including microdosing and microtracer technology, and physiology-based and population pharmacokinetic modeling, to contribute to a better understanding of the impact of age, disease and genetics on drug disposition in children.

read more

About this research group

We have elucidated ontogeny of hepatic, liver and intestinal drug transporters across the pediatric age range, using ex vivo studies (immunohistochemistry, RT-PCR, RNAseq and proteomics). Using innovative methods including microdosing and microtracer technology, physiology-based and population pharmacokinetic modeling, we contributed to a better understanding of the impact of age, disease and genetics on drug disposition in children.

To optimize off-label drug in children, we developed and validated a dose calculator, verified clinically implemented dose changes and participated in off-label policy statements. We also lead the recent extension of the Dutch Pediatric Formulary to country-specific formularies across Europe. As part of the EU research infrastructure initiatives we host the Conect4children Strategic Feasibility Advisory Service and the Dutch Pediatric Trial Network PEDMED-NL.


Research group leader

prof. dr. Saskia de Wildt

contact

Aims

Our group has several aims.

read more

Aims

Our research aims to elucidate variation in drug disposition and effect in special populations such as children and critically ill patients, taking into account age, disease and genetics. Human ex vivo, in vivo phenotyping, clinical trial as well as modeling and simulation approaches are used. Drug metabolism and membrane transport are focus of pharmacokinetic research, while pain/sedation and AKI are focus of pharmacodynamic research. We also aim to improve research infrastructure for pediatric clinical trials across Europe by participating at leadership level in several EU-funded initiatives. Clinical implementation of our and research from others is done trough the Dutch Pediatric Formulary, including model-informed dosing. The ultimate aim is to provide personalized effective and safe doses for special populations.